Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06366945

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Prospective, Single-arm, Phase II Clinical Study of Tirellizumab Combined With Carboplatin and Paclitaxel Polymer Micelles Neoadjuvant Therapy for cN+ Head and Neck Squamous Cell Carcinoma

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions HNSCC Head Cancer Neck Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

Interventions Carboplatin Polymeric Micellar Paclitaxel Post-operative radiation therapy Surgical Resection of Primary +/- Neck Dissection Tislelizumab

Updated 3 times since 2024 Last updated: Apr 15, 2024 Started: Apr 20, 2024 Primary completion: Dec 30, 2026 Completion: May 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HNSCC and Head Cancer Neck and is currently actively recruiting participants. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.